Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.

Abstract:

IMPORTANCE:Immune checkpoint inhibitor therapy has shown benefit in various cancers, but their potential in endometrial cancer (EC) is unknown. OBSERVATIONS:Prediction of neoantigen load was performed using sequencing data from the Cancer Genome Atlas data set. Evaluation of tumor-infiltrating lymphocytes (TILs) and PD-1 and PD-L1 expression was performed in 63 patients with EC referred to our institution. The predicted median (range) neoantigen load (predicted neoepitopes per sample) was proportional to the mutational load: highest in ultramutated polymerase e (POLE) tumors (8342 [628-20 440]), less in hypermutated MSI (541 [146-8063]; P < .001), and lowest in microsatellite-stable tumors (70.5 [7-1877]; P < .001). The POLE and MSI ECs exhibited higher numbers of CD3+ (44.5 vs 21.8; P = .001) and CD8+ (32.8 vs 13.5; P < .001) TILs compared with microsatellite-stable tumors. PD-1 was overexpressed in TILs (81% vs 28%; P < .001) and peritumoral lymphocytes (90% vs 28%; P < .001) of POLE and MSI tumors. PD-L1 expression was infrequently noted in tumor cells but was common in intraepithelial immune cells and more frequent in POLE and MSI tumors (39% vs 13%; P = .02). CONCLUSIONS AND RELEVANCE:Polymerase e-mutated and MSI ECs are associated with high neoantigen loads and number of TILs, which is counterbalanced by overexpression of PD-1 and PD-L1. Polymerase e-mutated and MSI EC tumors may be excellent candidates for PD-1-targeted immunotherapies.

journal_name

JAMA Oncol

journal_title

JAMA oncology

authors

Howitt BE,Shukla SA,Sholl LM,Ritterhouse LL,Watkins JC,Rodig S,Stover E,Strickland KC,D'Andrea AD,Wu CJ,Matulonis UA,Konstantinopoulos PA

doi

10.1001/jamaoncol.2015.2151

subject

Has Abstract

pub_date

2015-12-01 00:00:00

pages

1319-23

issue

9

eissn

2374-2437

issn

2374-2445

pii

2383137

journal_volume

1

pub_type

杂志文章
  • Willingness to Discuss Clinical Trials Among Black vs White Men With Prostate Cancer.

    abstract:Importance:Black individuals are underrepresented in cancer clinical trials. Objective:To examine whether Black and White men with prostate cancer differ in their willingness to discuss clinical trials with their physicians and, if so, whether patient-level barriers statistically mediate racial differences. Design, S...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.3697

    authors: Senft N,Hamel LM,Manning MA,Kim S,Penner LA,Moore TF,Carducci MA,Heath EI,Lansey DG,Albrecht TL,Wojda M,Jordan A,Eggly S

    更新日期:2020-09-17 00:00:00

  • Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study.

    abstract:IMPORTANCE:BRCA genetic testing has substantial public health impact, yet little is known of the real-world experiences of the more than 100 000 Americans undergoing testing annually. OBJECTIVE:To identify factors associated with use of BRCA testing, assess whether delivery of genetic counseling and testing services a...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.3048

    authors: Armstrong J,Toscano M,Kotchko N,Friedman S,Schwartz MD,Virgo KS,Lynch K,Andrews JE,Aguado Loi CX,Bauer JE,Casares C,Bourquardez Clark E,Kondoff MR,Molina AD,Abdollahian M,Walker G,Sutphen R

    更新日期:2015-12-01 00:00:00

  • Financial Relationships With Industry Among National Comprehensive Cancer Network Guideline Authors.

    abstract:Importance:Financial conflicts of interest (FCOIs) among authors of clinical practice guidelines have the potential to influence treatment recommendations. Objective:To quantify FCOIs with industry among authors of the National Comprehensive Cancer Network (NCCN) guidelines. Design, Setting, and Participants:We asses...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.2710

    authors: Mitchell AP,Basch EM,Dusetzina SB

    更新日期:2016-12-01 00:00:00

  • The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials.

    abstract:IMPORTANCE:Time to events, or survival end points, are common end points in randomized clinical trials. They are usually analyzed under the assumption of proportional hazards, and the treatment effect is reported as a hazard ratio, which is neither an intuitive measure nor a meaningful one if the assumption of proporti...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.6359

    authors: Péron J,Roy P,Ozenne B,Roche L,Buyse M

    更新日期:2016-07-01 00:00:00

  • Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases: The FIRE-SCLC Cohort Study.

    abstract:Importance:Although stereotactic radiosurgery (SRS) is preferred for limited brain metastases from most histologies, whole-brain radiotherapy (WBRT) has remained the standard of care for patients with small cell lung cancer. Data on SRS are limited. Objective:To characterize and compare first-line SRS outcomes (withou...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2020.1271

    authors: Rusthoven CG,Yamamoto M,Bernhardt D,Smith DE,Gao D,Serizawa T,Yomo S,Aiyama H,Higuchi Y,Shuto T,Akabane A,Sato Y,Niranjan A,Faramand AM,Lunsford LD,McInerney J,Tuanquin LC,Zacharia BE,Chiang V,Singh C,Yu JB,Brau

    更新日期:2020-07-01 00:00:00

  • Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.

    abstract:IMPORTANCE:Objective response rate (ORR) is an increasingly important end point for accelerated development of highly active anticancer therapies, yet its relationship to regulatory approval is not well characterized. OBJECTIVE:To identify circumstances in which a high ORR is associated with regulatory approval, and t...

    journal_title:JAMA oncology

    pub_type: 杂志文章,meta分析

    doi:10.1001/jamaoncol.2015.6315

    authors: Oxnard GR,Wilcox KH,Gonen M,Polotsky M,Hirsch BR,Schwartz LH

    更新日期:2016-06-01 00:00:00

  • Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial.

    abstract:IMPORTANCE:A recent randomized radiation dose-escalation trial in unresectable stage III non-small-cell lung cancer (NSCLC) (Radiation Therapy Oncology Group [RTOG] 0617) showed a lower survival rate in the high-dose radiation therapy (RT) arm (74 Gy) than in the low-dose arm (60 Gy) with concurrent chemotherapy. OBJE...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaoncol.2015.3969

    authors: Movsas B,Hu C,Sloan J,Bradley J,Komaki R,Masters G,Kavadi V,Narayan S,Michalski J,Johnson DW,Koprowski C,Curran WJ Jr,Garces YI,Gaur R,Wynn RB,Schallenkamp J,Gelblum DY,MacRae RM,Paulus R,Choy H

    更新日期:2016-03-01 00:00:00

  • Efficacy of Stereotactic Conformal Radiotherapy vs Conventional Radiotherapy on Benign and Low-Grade Brain Tumors: A Randomized Clinical Trial.

    abstract:Importance:Evidence for application of stereotactic and other conformal radiotherapy techniques in treating brain tumors is largely based on data derived from dosimetric, retrospective, or small prospective studies. Therefore, we conducted a randomized clinical trial of stereotactic conformal radiotherapy (SCRT) compar...

    journal_title:JAMA oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1001/jamaoncol.2017.0997

    authors: Jalali R,Gupta T,Goda JS,Goswami S,Shah N,Dutta D,Krishna U,Deodhar J,Menon P,Kannan S,Sarin R

    更新日期:2017-10-01 00:00:00

  • Association of Combined Modality Therapy vs Chemotherapy Alone With Overall Survival in Early-Stage Pediatric Hodgkin Lymphoma.

    abstract:Importance:To date, there is no well-defined standard of care for early-stage pediatric Hodgkin lymphoma (HL), which may include chemotherapy alone or combined modality therapy (CMT) with chemotherapy followed by radiotherapy. Although the use of radiotherapy in pediatric HL is decreasing, this strategy remains controv...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.5911

    authors: Jhawar SR,Rivera-Núñez Z,Drachtman R,Cole PD,Hoppe BS,Parikh RR

    更新日期:2019-05-01 00:00:00

  • Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.

    abstract:Importance:Low-cost sequencing of multiple genes is increasingly available for cancer risk assessment. Little is known about uptake or outcomes of multiple-gene sequencing after breast cancer diagnosis in community practice. Objective:To examine the effect of multiple-gene sequencing on the experience and treatment ou...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.0644

    authors: Kurian AW,Ward KC,Hamilton AS,Deapen DM,Abrahamse P,Bondarenko I,Li Y,Hawley ST,Morrow M,Jagsi R,Katz SJ

    更新日期:2018-08-01 00:00:00

  • Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer.

    abstract:Importance:The American Joint Committee on Cancer (AJCC) eighth edition staging manual introduced a new prognostic stage for breast cancer incorporating biologic factors in addition to traditional anatomic factors. Objective:To perform a validation study of the AJCC eighth edition prognostic stage in a single-institut...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2017.4298

    authors: Weiss A,Chavez-MacGregor M,Lichtensztajn DY,Yi M,Tadros A,Hortobagyi GN,Giordano SH,Hunt KK,Mittendorf EA

    更新日期:2018-02-01 00:00:00

  • Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review.

    abstract:Importance:Multiple myeloma (MM) is the second most common hematological malignant abnormality. The introduction of immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) has greatly improved the overall survival of patients with MM. Prevention and treatment of cardiovascular and thrombotic issues associated wi...

    journal_title:JAMA oncology

    pub_type: 杂志文章,评审

    doi:10.1001/jamaoncol.2016.3350

    authors: Li W,Garcia D,Cornell RF,Gailani D,Laubach J,Maglio ME,Richardson PG,Moslehi J

    更新日期:2017-07-01 00:00:00

  • Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.

    abstract:Importance:The benefit of adjuvant chemotherapy after resection of pancreatic cancer following neoadjuvant combination treatment with folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) is unclear. Objective:To assess the association of adjuvant chemotherapy with overall survival (OS) in patients afte...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.3537

    authors: van Roessel S,van Veldhuisen E,Klompmaker S,Janssen QP,Abu Hilal M,Alseidi A,Balduzzi A,Balzano G,Bassi C,Berrevoet F,Bonds M,Busch OR,Butturini G,Del Chiaro M,Conlon KC,Falconi M,Frigerio I,Fusai GK,Gagnière J,Grif

    更新日期:2020-09-10 00:00:00

  • Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma.

    abstract:Importance:The risk stratification of adrenocortical carcinoma (ACC) based on tumor proliferation index and stage is limited. Adjuvant therapy after surgery is recommended for most patients. Pan-genomic studies have identified distinct molecular groups closely associated with outcome. Objective:To compare the molecula...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2019.1558

    authors: Assié G,Jouinot A,Fassnacht M,Libé R,Garinet S,Jacob L,Hamzaoui N,Neou M,Sakat J,de La Villéon B,Perlemoine K,Ragazzon B,Sibony M,Tissier F,Gaujoux S,Dousset B,Sbiera S,Ronchi CL,Kroiss M,Korpershoek E,De Krijger

    更新日期:2019-07-11 00:00:00

  • Association Between Germline Mutation in VSIG10L and Familial Barrett Neoplasia.

    abstract:Importance:Esophageal adenocarcinoma and its precursor lesion Barrett esophagus have seen a dramatic increase in incidence over the past 4 decades yet marked genetic heterogeneity of this disease has precluded advances in understanding its pathogenesis and improving treatment. Objective:To identify novel disease susce...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.2054

    authors: Fecteau RE,Kong J,Kresak A,Brock W,Song Y,Fujioka H,Elston R,Willis JE,Lynch JP,Markowitz SD,Guda K,Chak A

    更新日期:2016-10-01 00:00:00

  • Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.

    abstract:Importance:Sorafenib is the first-line treatment for hepatocellular carcinoma with portal vein invasion; however, it has shown unsatisfactory survival benefit. Sorafenib plus hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and leucovorin (FOLFOX) has shown promising results for these patient...

    journal_title:JAMA oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1001/jamaoncol.2019.0250

    authors: He M,Li Q,Zou R,Shen J,Fang W,Tan G,Zhou Y,Wu X,Xu L,Wei W,Le Y,Zhou Z,Zhao M,Guo Y,Guo R,Chen M,Shi M

    更新日期:2019-07-01 00:00:00

  • Time to Surgery and Breast Cancer Survival in the United States.

    abstract:IMPORTANCE:Time to surgery (TTS) is of concern to patients and clinicians, but controversy surrounds its effect on breast cancer survival. There remains little national data evaluating the association. OBJECTIVE:To investigate the relationship between the time from diagnosis to breast cancer surgery and survival, usin...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.4508

    authors: Bleicher RJ,Ruth K,Sigurdson ER,Beck JR,Ross E,Wong YN,Patel SA,Boraas M,Chang EI,Topham NS,Egleston BL

    更新日期:2016-03-01 00:00:00

  • Safety and Feasibility of Using Magnetic Resonance Imaging Criteria to Identify Patients With "Good Prognosis" Rectal Cancer Eligible for Primary Surgery: The Phase 2 Nonrandomized QuickSilver Clinical Trial.

    abstract:Importance:Chemoradiotherapy (CRT), followed by surgery, is the recommended approach for stage II and III rectal cancer. While CRT decreases the risk of local recurrence, it does not improve survival and leads to poorer functional outcomes than surgery alone. Therefore, new approaches to better select patients for CRT ...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2019.0186

    authors: Kennedy ED,Simunovic M,Jhaveri K,Kirsch R,Brierley J,Drolet S,Brown C,Vos PM,Xiong W,MacLean T,Kanthan S,Stotland P,Raphael S,Chow G,O'Brien CA,Cho C,Streutker C,Wong R,Schmocker S,Liberman S,Reinhold C,Kopek N

    更新日期:2019-07-01 00:00:00

  • Association of Body Mass Index and Age With Subsequent Breast Cancer Risk in Premenopausal Women.

    abstract:Importance:The association between increasing body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) and risk of breast cancer is unique in cancer epidemiology in that a crossover effect exists, with risk reduction before and risk increase after menopause. The inverse association w...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2018.1771

    authors: Premenopausal Breast Cancer Collaborative Group.,Schoemaker MJ,Nichols HB,Wright LB,Brook MN,Jones ME,O'Brien KM,Adami HO,Baglietto L,Bernstein L,Bertrand KA,Boutron-Ruault MC,Braaten T,Chen Y,Connor AE,Dorronsoro M,Dossu

    更新日期:2018-11-01 00:00:00

  • Association of Obesity With Risk of Early-Onset Colorectal Cancer Among Women.

    abstract:Importance:Colorectal cancer (CRC) incidence and mortality among individuals younger than 50 years (early-onset CRC) are increasing. The reasons for such increases are largely unknown, although the increasing prevalence of obesity may be partially responsible. Objective:To investigate prospectively the association bet...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.4280

    authors: Liu PH,Wu K,Ng K,Zauber AG,Nguyen LH,Song M,He X,Fuchs CS,Ogino S,Willett WC,Chan AT,Giovannucci EL,Cao Y

    更新日期:2019-01-01 00:00:00

  • Aspirin Use and Risk of Colorectal Cancer Among Older Adults.

    abstract:Importance:Although aspirin is recommended for the prevention of colorectal cancer (CRC) among adults aged 50 to 59 years, recent data from a randomized clinical trial suggest a lack of benefit and even possible harm among older adults. Objective:To examine the association between aspirin use and the risk of incident ...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.7338

    authors: Guo CG,Ma W,Drew DA,Cao Y,Nguyen LH,Joshi AD,Ng K,Ogino S,Meyerhardt JA,Song M,Leung WK,Giovannucci EL,Chan AT

    更新日期:2021-01-21 00:00:00

  • Association of a Bundled-Payment Program With Cost and Outcomes in Full-Cycle Breast Cancer Care.

    abstract:Importance:Value-driven payment system reform is a potential tool for aligning economic incentives with the improvement of quality and efficiency of health care and containment of cost. Such a payment system has not been researched satisfactorily in full-cycle cancer care. Objective:To examine the association of outco...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.4549

    authors: Wang CJ,Cheng SH,Wu JY,Lin YP,Kao WH,Lin CL,Chen YJ,Tsai SL,Kao FY,Huang AT

    更新日期:2017-03-01 00:00:00

  • Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: A Nonrandomized Controlled Trial.

    abstract:Importance:Currently, preoperative radiotherapy for all soft-tissue sarcomas is identical at a 50-Gy dose level, which can be associated with morbidity, particularly wound complications. The observed clinical radiosensitivity of the myxoid liposarcoma subtype might offer the possibility to reduce morbidity. Objective:...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.5865

    authors: Lansu J,Bovée JVMG,Braam P,van Boven H,Flucke U,Bonenkamp JJ,Miah AB,Zaidi SH,Thway K,Bruland ØS,Baldini EH,Jebsen NL,Scholten AN,van den Ende PLA,Krol ADG,Ubbels JF,van der Hage JA,van Werkhoven E,Klomp HM,van der

    更新日期:2021-01-01 00:00:00

  • Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.

    abstract:Importance:Remarkable progress has occurred in understanding the pathophysiology and in developing improved personalized therapies in adult acute lymphoblastic leukemia (ALL). Observations:We searched MEDLINE (1990-2018), the American Society of Clinical Oncology, and American Society of Hematology websites (2010-2018...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.1915

    authors: Jabbour E,Pui CH,Kantarjian H

    更新日期:2018-10-01 00:00:00

  • Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study.

    abstract:Importance:Single-agent immune checkpoint inhibition has not shown activities in advanced refractory colorectal cancer (CRC), other than in those patients who are microsatellite-instability high (MSI-H). Objective:To evaluate whether combining programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated pro...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaoncol.2020.0910

    authors: Chen EX,Jonker DJ,Loree JM,Kennecke HF,Berry SR,Couture F,Ahmad CE,Goffin JR,Kavan P,Harb M,Colwell B,Samimi S,Samson B,Abbas T,Aucoin N,Aubin F,Koski SL,Wei AC,Magoski NM,Tu D,O'Callaghan CJ

    更新日期:2020-06-01 00:00:00

  • Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.

    abstract:Importance:Unresectable intrahepatic cholangiocarcinoma (IHC) carries a poor prognosis, with a median overall survival (OS) of 11 months. Hepatic arterial infusion (HAI) of high-dose chemotherapy may have potential benefit in these patients. Objective:To evaluate clinical outcomes when HAI chemotherapy is combined wit...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2019.3718

    authors: Cercek A,Boerner T,Tan BR,Chou JF,Gönen M,Boucher TM,Hauser HF,Do RKG,Lowery MA,Harding JJ,Varghese AM,Reidy-Lagunes D,Saltz L,Schultz N,Kingham TP,D'Angelica MI,DeMatteo RP,Drebin JA,Allen PJ,Balachandran VP,Lim

    更新日期:2019-10-31 00:00:00

  • Effect of Delayed Targeted Intraoperative Radiotherapy vs Whole-Breast Radiotherapy on Local Recurrence and Survival: Long-term Results From the TARGIT-A Randomized Clinical Trial in Early Breast Cancer.

    abstract:Importance:Conventional adjuvant radiotherapy for breast cancer given daily for several weeks is onerous and expensive. Some patients may be obliged to choose a mastectomy instead, and some may forgo radiotherapy altogether. We proposed a clinical trial to test whether radiotherapy could be safely limited to the tumor ...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaoncol.2020.0249

    authors: Vaidya JS,Bulsara M,Saunders C,Flyger H,Tobias JS,Corica T,Massarut S,Wenz F,Pigorsch S,Alvarado M,Douek M,Eiermann W,Brew-Graves C,Williams N,Potyka I,Roberts N,Bernstein M,Brown D,Sperk E,Laws S,Sütterlin M,Lu

    更新日期:2020-07-01 00:00:00

  • Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.

    abstract:Importance:Hand-foot syndrome (HFS) is a common adverse effect of capecitabine treatment. Objective:To compare the incidence and time to onset of grade 2 or greater HFS in patients receiving pyridoxine vs placebo and to identify biomarkers predictive of HFS. Design, Setting, and Participants:This single-center, rando...

    journal_title:JAMA oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1001/jamaoncol.2017.1269

    authors: Yap YS,Kwok LL,Syn N,Chay WY,Chia JWK,Tham CK,Wong NS,Lo SK,Dent RA,Tan S,Mok ZY,Koh KX,Toh HC,Koo WH,Loh M,Ng RCH,Choo SP,Soong RCT

    更新日期:2017-11-01 00:00:00

  • Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.

    abstract:Importance:A significant proportion of patients with early-stage triple-negative breast cancer (TNBC) are treated with neoadjuvant chemotherapy. Sequencing of circulating tumor DNA (ctDNA) after surgery, along with enumeration of circulating tumor cells (CTCs), may be used to detect minimal residual disease and assess ...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.2295

    authors: Radovich M,Jiang G,Hancock BA,Chitambar C,Nanda R,Falkson C,Lynce FC,Gallagher C,Isaacs C,Blaya M,Paplomata E,Walling R,Daily K,Mahtani R,Thompson MA,Graham R,Cooper ME,Pavlick DC,Albacker LA,Gregg J,Solzak JP,C

    更新日期:2020-09-01 00:00:00

  • Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 Trial.

    abstract:Importance:Consensus is lacking as to the optimal radiotherapy dose and fractionation schedule for treating bone metastases. Objective:To assess the relative efficacy of high-dose, single-fraction stereotactic body radiotherapy (SBRT) vs standard multifraction radiotherapy (MFRT) for alleviation of pain in patients wi...

    journal_title:JAMA oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1001/jamaoncol.2019.0192

    authors: Nguyen QN,Chun SG,Chow E,Komaki R,Liao Z,Zacharia R,Szeto BK,Welsh JW,Hahn SM,Fuller CD,Moon BS,Bird JE,Satcher R,Lin PP,Jeter M,O'Reilly MS,Lewis VO

    更新日期:2019-06-01 00:00:00